Literature DB >> 22000778

Biventricular performance in patients with marfan syndrome without significant valvular disease: comparison to normal subjects and longitudinal follow-up.

Roderick W C Scherptong1, Hubert W Vliegen, Ernst E van der Wall, Yvonne Hilhorst-Hofstee, Jeroen J Bax, Arthur J Scholte, Victoria Delgado.   

Abstract

BACKGROUND: The presence and progressive nature of primary myocardial involvement in Marfan syndrome are debated. The aim of this study was to evaluate the clinical relevance of left ventricular (LV) and right ventricular (RV) strain in adult patients with Marfan syndrome without significant valvular disease.
METHODS: Adult patients with Marfan syndrome (n = 50; mean age, 35.2 ± 12.9 years) were followed prospectively. Echocardiography was performed annually and consisted of comprehensive assessment of ventricular and valvular function. Using speckle-tracking imaging, the baseline strain values of the Marfan population were calculated and compared with the values of normal controls. The follow-up evaluations were used to assess changes in ventricular strain. The association between the incidence of adverse events (heart failure, [supra]ventricular arrhythmias, and proximal aorta surgery) and baseline strain values was investigated.
RESULTS: Compared with controls, patients with Marfan syndrome had significantly lower peak longitudinal LV strain (-18.9 ± 2.3% vs -20.1 ± 1.9%, P < .01) and RV strain (±26.9 ± 5.2% vs ±29.3 ± 4.25%, P < .01). The absolute changes in LV longitudinal, radial, and circumferential strain and RV longitudinal strain during a median 4 years of follow-up were 0.1 ± 2.8%, 1.12 ± 7.6%, 0.3 ± 3.7%, and 0.9 ± 5.5%, respectively, which was not statistically significant. Cox regression demonstrated that reduced LV or RV strain was not associated with adverse outcome (supraventricular arrhythmias, n = 3; proximal aorta surgery, n = 4).
CONCLUSIONS: This study suggests that patients with Marfan syndrome show lower ventricular strain and strain rate values compared with healthy controls. However, no relevant changes in LV and RV function occurred during midterm follow-up in patients with Marfan syndrome without valvular disease at baseline. Although ventricular strain and strain rate were mildly reduced in patients with Marfan syndrome, this did not affect outcomes negatively in the present study.
Copyright © 2011 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22000778     DOI: 10.1016/j.echo.2011.09.004

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  6 in total

1.  Intrinsic cardiomyopathy in Marfan syndrome: results from in-vivo and ex-vivo studies of the Fbn1C1039G/+ model and longitudinal findings in humans.

Authors:  Laurence Campens; Marjolijn Renard; Bram Trachet; Patrick Segers; Laura Muino Mosquera; Johan De Sutter; Lynn Sakai; Anne De Paepe; Julie De Backer
Journal:  Pediatr Res       Date:  2015-06-04       Impact factor: 3.756

2.  Genotype-phenotype analysis of F-helix mutations at the kinase domain of TGFBR2, including a type 2 Marfan syndrome familial study.

Authors:  Lin Zhang; Ling-Gen Gao; Ming Zhang; Xian-Liang Zhou
Journal:  Mol Vis       Date:  2012-01-11       Impact factor: 2.367

3.  Smooth muscle LDL receptor-related protein-1 deletion induces aortic insufficiency and promotes vascular cardiomyopathy in mice.

Authors:  Joshua E Basford; Sheryl Koch; Ahmad Anjak; Vivek P Singh; Eric G Krause; Nathan Robbins; Neal L Weintraub; David Y Hui; Jack Rubinstein
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

4.  NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome.

Authors:  Petra Gehle; Peter N Robinson; Frank Heinzel; Frank Edelmann; Mustafa Yigitbasi; Felix Berger; Volkmar Falk; Burkert Pieske; Ernst Wellnhofer
Journal:  Int J Cardiol Heart Vasc       Date:  2016-05-18

5.  Ventricular-Vascular Coupling in Marfan and Non-Marfan Aortopathies.

Authors:  Farina Loeper; Jantine Oosterhof; Mark van den Dorpel; Denise van der Linde; Yaxin Lu; Elizabeth Robertson; Brett Hambly; Richmond Jeremy
Journal:  J Am Heart Assoc       Date:  2016-11-16       Impact factor: 5.501

Review 6.  Cardiomyopathy in Genetic Aortic Diseases.

Authors:  Laura Muiño-Mosquera; Julie De Backer
Journal:  Front Pediatr       Date:  2021-07-15       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.